e-learning
resources
Paris 2018
Sunday, 16.09.2018
New developments in the treatment of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy and safety of extrafine glycopyrronium bromide (GB) in uncontrolled asthmatic patients
P. Paggiaro (Pisa, Italy), G. Georges (Cary, United States of America), M. Scuri (Parma, Italy), I. Valente (Parma, Italy), A. Guasconi (Parma, Italy), S. Corre (Parma, Italy), A. Papi (Ferrara, Italy)
Source:
International Congress 2018 – New developments in the treatment of asthma
Session:
New developments in the treatment of asthma
Session type:
Thematic Poster
Number:
1027
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Paggiaro (Pisa, Italy), G. Georges (Cary, United States of America), M. Scuri (Parma, Italy), I. Valente (Parma, Italy), A. Guasconi (Parma, Italy), S. Corre (Parma, Italy), A. Papi (Ferrara, Italy). Efficacy and safety of extrafine glycopyrronium bromide (GB) in uncontrolled asthmatic patients. 1027
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Extrafine glycopyrronium bromide (GB) in addition to extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FF) in uncontrolled asthmatic patients
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018
Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012
Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Efficacy of formoterol 12μg dry powder capsules in 6,155 asthmatic patients poorly controlled with salmeterol or on-demand salbutamol (EFORA study)
Source: Eur Respir J 2002; 20: Suppl. 38, 107s
Year: 2002
Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients
Source: Annual Congress 2010 - Bronchodilators in airways disease
Year: 2010
Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
Safety and tolerability of high-dose formoterol
via
aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 285s
Year: 2003
Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Efficacy and safety of transdermal tulobuterol (LABA) on asthma patients
Source: Annual Congress 2007 - New treatments for asthma
Year: 2007
Tiotropium bromide: Efficacy and safety in complex treatment of COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017
Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects
Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Year: 2010
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination
vs.
fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006
Cost effectiveness of umeclidinium bromide 62.5µg plus ICS/LABA versus ICS/LABA in COPD
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept